Will Orexigen Have the Last Laugh?

When looking at the obesity drug space, investors tend to focus on VIVUS' (NASDAQ: VVUS  ) Qsymia and Arena Pharmaceuticals' (NASDAQ: ARNA  )  Belviq.

But have they already forgotten about the third potential player: Orexigen Therapeutics (NASDAQ: OREX  ) ?

Orexigen's success hinges on approval from the Food and Drug Administration on its weight-loss drug Contrave, and the company released news today that suggests it is inching its way closer to a final decision. In the following video, health care analyst Max Macaluso breaks down the news, explains why shares of Orexigen were static today, and also notes one major risk that investors can't ignore with this stock.

What's inside Supernova?
If you're an investor looking for big long-term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.

Read/Post Comments (11) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 07, 2013, at 3:17 PM, RSRdriver wrote:

    Even though something tells me your mom's basement is behind that screen, you actually make a lot of good points.

    When one looks at the Vivus/J+J lawsuit potential and Arena's efficacy and Eisai entanglements, OREX is really the only real buyout candidate as well.

  • Report this Comment On January 08, 2013, at 10:08 AM, Jinmeif88 wrote:

    Just forget about Contrave for a while. The required testing procedures will not complete until early 2014 plus the time to resubmit the application -- and the FDA review time, --- So take a nap, a good nap for that one.

  • Report this Comment On January 08, 2013, at 12:32 PM, RSRdriver wrote:

    The play on OREX is into the event stage which should start this quarter. No one here is recomending a long term investment. If you don't know what a trade is, stick to the BS slinging on the ARNA message boards.

  • Report this Comment On January 08, 2013, at 1:04 PM, MannyGoldberg wrote:

    I am an experienced Bariatric Physician, well versed in medical treatment of obesity, as well as FDA approval, as a former Principla Investigator.

    It is humorous to read the author's positive comments about Contrave, which is a long way from FDA approval. I recoomend you take a Wellbutrin daily as well as Narcan daily for a week, and report back how you feel.

    Wellbutrin makes many patients feel like a "zombie" and Narcan will reverse any pain-relieving narcotic like medications, throwing them into "cold turkey" withdrawal pain..

    Can you see a zombie in pain actually wanting to refill a Rx for Contrave, even if it is approved?

  • Report this Comment On January 08, 2013, at 1:09 PM, RSRdriver wrote:

    Another Areniac "doctor". Just what ARNA longs need.

    You guys do more harm to the PPS than the puny efficacy. Keep it coming DH's.

  • Report this Comment On January 08, 2013, at 1:22 PM, MannyGoldberg wrote:

    RS Driver,

    You are right........ I have over 250 patients (many are also diabetics) I plan to start on Belviq (I already have over 50 on Qsymia). I hate writing Rxs for Qsymia, like many M.D.s, but many I plan to switch to Belviq when they plateau. Contrave I dont ever plan to use, like many of my bariatric colleagues,

  • Report this Comment On January 08, 2013, at 1:25 PM, RSRdriver wrote:

    This Areniac BS is getting old. Try that crap over at the Yahoo Message board.

  • Report this Comment On January 08, 2013, at 1:26 PM, MannyGoldberg wrote:

    RS Driver,

    One more thing.....the efficacy issue is solid with Belviq....8% in a year, with 25% losing over 16%! This might not sound like much to the lay public, but it definitely makes a huge difference in

    blood sugar control, back pain, sleep apnea, and the horrible chronic pain of osteoarthritis.

  • Report this Comment On January 08, 2013, at 1:30 PM, RSRdriver wrote:

    I see your slinging Reza's numbers. You guy's are hilarious. EVERYONE KNOWS BELVIQ IS USELESS!

  • Report this Comment On January 08, 2013, at 1:36 PM, MannyGoldberg wrote:

    Sounds like you are already taking Contrave.....LOL.

    Unfortunately for you, you are wrong, but you won't be writing the Rxs, will you?.....

    Guess who will??

  • Report this Comment On January 08, 2013, at 1:45 PM, RSRdriver wrote:

    You know, there SEC laws in place that are specifically used to cover fraud by impersonation. Check them out.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2182673, ~/Articles/ArticleHandler.aspx, 9/28/2016 5:10:38 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 7 hours ago Sponsored by:
DOW 18,228.30 133.47 0.74%
S&P 500 2,159.93 13.83 0.64%
NASD 5,305.71 48.22 0.92%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/27/2016 4:00 PM
OREX $3.24 Down +0.00 +0.00%
Orexigen Therapeut… CAPS Rating: **
ARNA $1.81 Up +0.08 +4.62%
Arena Pharmaceutic… CAPS Rating: ***
VVUS $1.20 Down -0.04 -3.23%
VIVUS CAPS Rating: **